Chemours Co. (NYSE:CC) has been given a consensus recommendation of “Hold” by the nine ratings firms that are currently covering the firm. One research analyst has rated the stock with a sell rating, six have given a hold rating and two have issued a buy rating on the company. The average 12-month price target among brokers that have issued ratings on the stock in the last year is $16.09.
A number of research analysts have weighed in on the stock. Zacks Investment Research downgraded shares of Chemours from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, November 1st. Jefferies Group reiterated a “hold” rating and issued a $17.00 price objective (up previously from $15.00) on shares of Chemours in a research report on Thursday, November 10th. Finally, Goldman Sachs Group Inc. downgraded shares of Chemours from a “buy” rating to a “neutral” rating and upped their price objective for the stock from $23.00 to $27.00 in a research report on Monday, December 12th.
Shares of Chemours (NYSE:CC) opened at 24.99 on Friday. The company has a market cap of $4.54 billion, a P/E ratio of 30.25 and a beta of 3.45. The firm has a 50-day moving average of $23.92 and a 200 day moving average of $16.23. Chemours has a 52 week low of $3.06 and a 52 week high of $27.29.
Hedge funds have recently added to or reduced their stakes in the company. Advisor Partners LLC boosted its stake in shares of Chemours by 5.0% in the second quarter. Advisor Partners LLC now owns 12,156 shares of the company’s stock valued at $100,000 after buying an additional 580 shares in the last quarter. Seaward Management Limited Partnership boosted its stake in shares of Chemours by 16.3% in the second quarter. Seaward Management Limited Partnership now owns 12,568 shares of the company’s stock valued at $103,000 after buying an additional 1,765 shares in the last quarter. LS Investment Advisors LLC boosted its stake in shares of Chemours by 3.9% in the third quarter. LS Investment Advisors LLC now owns 6,997 shares of the company’s stock valued at $112,000 after buying an additional 265 shares in the last quarter. Ameritas Investment Partners Inc. acquired a new stake in shares of Chemours during the second quarter valued at about $118,000. Finally, Quantbot Technologies LP acquired a new stake in shares of Chemours during the third quarter valued at about $124,000. 74.38% of the stock is owned by institutional investors and hedge funds.
Chemours Company Profile
The Chemours Company is a provider of performance chemicals. The Company operates through three segments: Titanium Technologies, Fluoroproducts and Chemical Solutions. The Company’s Titanium Technologies segment manufactures titanium dioxide (TiO2), which is a pigment used to deliver whiteness, opacity, brightness and protection from sunlight in applications, such as architectural and industrial coatings, plastic packaging, polyvinyl chloride (PVC) window profiles, laminate papers, coated paper and coated paperboard used for packaging.